Sixfold Bioscience

Sixfold Bioscience is a private, pre-clinical stage biotech pioneering a novel approach to RNA therapeutic delivery. Its proprietary Mergo® platform uses machine learning and evolutionary principles to design programmable RNA tags that direct therapeutic RNA to specific cells, addressing the major industry bottleneck of extra-hepatic delivery. Founded by Dr. Anna Perdrix Rosell and Dr. George Foot, the company has assembled a multidisciplinary team of over 20 to advance its platform and build a pipeline of RNA therapies for genetic diseases. While holding significant potential, the company faces risks inherent to novel platform validation and the competitive drug delivery landscape.

Mergo® platform: an AI-powered system for designing programmable RNA tags that direct therapeutic RNA to specific cell types, inspired by natural, unencapsulated RNA delivery mechanisms.

Sixfold competes in the crowded RNA delivery space against companies developing advanced lipid nanoparticles (e.g., Acuitas, Genevant), ligand-conjugated platforms (e.g., Alnylam's GalNAc), and viral vectors. Its differentiation lies in its biologically-inspired, unencapsulated approach and its integrated AI/ML-driven design cycle.